Why the study?
Reduced renal blood flow activates the RAAS causing renovascular hypertension, and the study investigated whether Ang II alters renal vascular smooth muscle sGC expression through an AT1R-FoxO transcription factor mechanism.
Angiotensin II upregulates soluble guanylyl cyclase expression in renal vascular smooth muscle via AT1R and FoxO, suggesting a compensatory protective mechanism to improve renal blood flow during RAAS activation.
Hypothesis-generating for compensatory renal sGC upregulation during RAAS activation; leaves open human translation.
Background and Purpose: Reduced renal blood flow triggers activation of the renin-angiotensin-aldosterone system (RAAS) leading to renovascular hypertension. Renal vascular smooth muscle expression of the nitric oxide (NO) receptor, soluble guanylyl cyclase (sGC), modulates the vasodilatory response needed to control renal vascular tone and blood flow. Here, we tested if angiotensin II (Ang II) impacts sGC expression via an Ang II type 1 receptor (AT 1 R) -forkhead box subclass O (FoxO) transcription factor dependent mechanism. Experimental Approach: Using a murine 2-kidney-1-clip (2K1C) renovascular hypertension model, we measured renal artery vasodilatory function and sGC expression. Additionally, we conducted cell culture studies using rat renal pre-glomerular smooth muscle cells (RPGSMCs) to test the in vitro mechanistic effects of Ang II treatment on sGC expression and downstream function. Key Results: Contralateral, unclipped renal arteries in 2K1C mice showed increased NO – dependent vasorelaxation compared to sham control mice. Immunofluorescence studies revealed increased sGC protein expression in contralateral unclipped renal arteries over sham controls. RPGSMCs treated with Ang II caused a significant upregulation of sGC mRNA and protein expression as well as downstream sGC-dependent signaling. Ang II signaling effects on sGC expression occurred through an AT 1 R and FoxO transcription factor – dependent mechanism at both the mRNA and protein expression levels. Conclusion and Implications: Renal artery smooth muscle, in vivo and in vitro, upregulate expression of sGC following RAAS activity. In both cases, upregulation of sGC leads to elevated downstream cGMP signaling, suggesting a previously unrecognized protective mechanism to improve renal blood flow.
No takes yet. Share an insight, caveat, or question.
Galley et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: